Form 4: Belite Bio Insider Sells Shares Under 10b5-1 Plan

Belite Bio's Chief Scientific Officer, Nathan L. Mata, reported the sale of American depositary shares under a pre-arranged trading plan.

Summary

• Nathan L. Mata, Chief Scientific Officer of Belite Bio, Inc., reported transactions on May 5, 2026.
• These transactions involved the sale of American depositary shares (ADS) under a Rule 10b5-1 trading plan.
• The sales occurred at various weighted average prices ranging from $153.92 to $157.99.
• The total number of shares sold is not explicitly stated but can be inferred from the changes in beneficial ownership.
• Following these transactions, Mr. Mata's beneficial ownership of ADS has decreased.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider selling can be a negative signal, the transaction was executed under a pre-arranged 10b5-1 plan, mitigating concerns about opportunistic trading.

Negatives

• Insider selling activity can sometimes be perceived negatively by the market, although this sale was conducted under a pre-established 10b5-1 plan.

Risks

• The Rule 10b5-1 plan is designed to provide an affirmative defense against allegations of insider trading, but the execution of such plans can still be subject to market interpretation.
• The specific reasons for the sales under the 10b5-1 plan are not detailed, which could lead to speculation.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding future financial performance or strategic initiatives.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common for executives managing their personal finances and liquidity, especially in the biotechnology sector where stock-based compensation is prevalent. The key is that these plans are established when the insider does not possess material non-public information.

Stakeholder Impact

• Shareholders: May interpret insider sales, even under a 10b5-1 plan, as a signal of reduced confidence or a need for liquidity, potentially impacting share price sentiment.
• Management: The use of a 10b5-1 plan demonstrates adherence to compliance procedures for managing personal stock transactions.

Key Dates

Keywords

Belite Bio, BLTE, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, ADS, Nathan L. Mata, Securities Exchange Act